|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Bharat Biotech Vaccine Doses Touch 1 Billion
2/4/2010 2:13:15 PM
Hyderabad, India, February 3, 2010: Bharat Biotech announced today that it just delivered its 1 billionth vaccine dose. This accomplishment demonstrates the determination and dedication of Bharat Biotech in providing health care solutions to millions of people in India and the developing world. Bharat Biotech is a global manufacturer of vaccines to protect against rabies, polio, hepatitis-B, typhoid, diphtheria, pertussius, tetanus, haemophilus influenza B and other diseases.
“This is a symbolic moment for Bharat Biotech, since it documents our past performance while laying the foundation for our future growth” Dr. Krishna M. Ella, Chairman and Managing Director said,
Commenting on this milestone event, Dr. Ella further added; “While the manufacture and sale of a billion doses gives us a great sense of pride and accomplishment, we at Bharat Biotech realize that life saving vaccines are still unavailable to millions of people and there is a lot more work to be done. We are truly committed to research and development of innovative vaccines to address global infectious diseases”
Bharat Biotech has cultivated a strong culture of innovation with focus on infectious diseases of the developing world.Bharat Biotech has novel vaccine development projects such as rotavirus vaccine, typhoid conjugate vaccine, malaria vaccine, Japanese encephalitis vaccine, chikungunya vaccine, pandemic/seasonal influenza vaccine etc.
The Future growth strategy at Bharat Biotech is well laid out with a combination of high volume WHO prequalified vaccines and innovative novel vaccines catering to the needs of developing world populations.
Going forward Bharat Biotech intends to further strengthen its clinical research activities through a series of investments into safety and efficacy clinical trials for its innovative vaccines and therapeutics. The company intends to inject 30% of its revenues in R& D and Clinical Research.
It has taken Bharat Biotech ~ 10 years to reach its first billion doses, the 2nd billion doses would reached in less than 5 years” Dr. Ella said.
About Bharat Biotech International Limited
Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech is also a WHO prequalified manufacturer of Hepatitis-B vaccines for supply to UNICEF and global procurement agencies. Bharat Biotech is one of the largest manufacturer of anti-rabies vaccines in India. INDIRAB® is a market leader in India and several countries globally.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.
|
|
|
|
|
|
|
|
|
|
|